Selexis SA

KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings

Cell line development,hts,cell line engineering,contract biological services,stable cell line development,cell engineering,variant screening,research cell banks,monoclonal antibodies,whole genome sequencing,bispecific antibodies,cdmo,monoclonality assessment,biotechnology,biosimilars,cell line engineering,genetic engineering,mammalian cell line,biotherapeutics,and multispecific antibodies

Selexis sa operates in the Biotechnology research industry.

Selexis sa's revenue is 11m - 100m

Selexis sa has 11 - 50 employees.